Our understanding of the biology of the innate immune systems is rapidly expanding. We are gaining an increasing understanding of the receptors expressed by NK cells that specifically mediate the inhibition and activation of these cells, as well as the ligands for these receptors. It is becoming clear that innate immune signals can dramatically modulate adaptive immune response. Emerging data are implicating NK cells and Other innate immune responses in the early control of HIV-1 replication during primary infection. The recent demonstration that it is possible to generate memory responses in the innate immune system raises the possibility that it may be feasible to use vaccines to enhance anti-viral innate immunity to help terminate or control very early HIV-1 infection. We will explore this possibility in the following aims:
Aim 1. Recombinant canary-pox elicited innate responses and their contribution to shaping adaptive immune responses in rhesus monkeys Aim 2. Vaccination with KIR ligands for induction of immunologic memory for innate NK cell responses in rhesus monkeys and humans Aim 3. CD8+ T cell-produced factors and control of viremia The information gained in these studies about the anti-SIV and anti-HIV protective capacity of innate immune responses will lead directly to advances in vaccine design.

Public Health Relevance

Early in acute HIV-1 infection innate immune responses are activated and evidence suggests that they are important in the potential control of the virus. Recent studies suggest a form of virus-induced innate memory. Therefore, it is important to determine if HlV-1 vaccines can induce innate memory to augment protective immune responses to HIV-1 infection.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Pardi, Norbert; Hogan, Michael J; Naradikian, Martin S et al. (2018) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215:1571-1588
Eudailey, Joshua A; Dennis, Maria L; Parker, Morgan E et al. (2018) Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques. mSphere 3:
Kelsoe, Garnett; Haynes, Barton F (2018) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Cold Spring Harb Perspect Biol 10:
Wagh, Kshitij; Kreider, Edward F; Li, Yingying et al. (2018) Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Rep 25:893-908.e7
Fu, Qingshan; Shaik, Md Munan; Cai, Yongfei et al. (2018) Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A 115:E8892-E8899
Fera, Daniela; Lee, Matthew S; Wiehe, Kevin et al. (2018) HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. Nat Commun 9:1111
McMichael, Andrew J (2018) Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? Could a CD8+ T-Cell Vaccine Prevent Persistent HIV Infection? Cold Spring Harb Perspect Biol 10:
Williams, Wilton B; Han, Qifeng; Haynes, Barton F (2018) Cross-reactivity of HIV vaccine responses and the microbiome. Curr Opin HIV AIDS 13:9-14
Bonsignori, Mattia; Scott, Eric; Wiehe, Kevin et al. (2018) Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity 49:1162-1174.e8
Blasi, Maria; Negri, Donatella; LaBranche, Celia et al. (2018) IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Commun Biol 1:134

Showing the most recent 10 out of 261 publications